<DOC>
	<DOC>NCT00039026</DOC>
	<brief_summary>This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.</brief_summary>
	<brief_title>Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subjects with Type 2 diabetes mellitus Treated with a sulfonylurea at defined doses for at least 3 months prior to screening BMI= 2745 kg/m2 HbA1c value between 7.5% and 11% Treated with oral antidiabetic medications other than a sulfonylurea within 3 months of screening Patients treated previously with AC2993 Patients presently treated with insulin</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitis</keyword>
</DOC>